Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera… Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE)- 5-year follow up of a phase 3 study RETOUR MarcGuevreguian2021-03-22T20:20:53+01:00